Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars
Joanne Grant

Chris Vindurampulle PhD

Executive, Patent & Trade Mark Attorney (Head of Patent Prosecution)

PhD, MCommrclLaw, BSc (Hons)
Doctor of Philosophy (Microbiology and Immunology)
Masters of Commercial Law
Bachelor of Science (Hons) in Microbiology and Immunology
Registered Patent and Trade Mark Attorney (AU, NZ)

Chris is a senior patent and trade mark attorney who is registered to practice before the intellectual property offices of Australia and New Zealand. He is experienced in patent drafting, patent and trade mark prosecution and opposition, and freedom to operate, opinion and due diligence work. Through his experience and delivery of highly-regarded client service, Chris has been recognised as a leading patent practitioner having been listed in the IAM Patent 1000 as a recommended individual for patent prosecution, and a Rising Star in 2021 and 2022 by Managing IP.

During his career as an IP specialist, Chris has gained broad and significant experience in relation to biopharma (including pharmaceuticals and biologics), biotechnology, medical devices, diagnostics, methods of medical treatment and prevention, agritechnology (including plant breeders rights, animal and plant transgenics, pesticides and machinery) and food-technology (products and processing technology). Additionally, Chris has experience with alloy design and production, metal casting and processing, and hydrocarbon processing.

Chris’ PhD thesis investigated a phenomenon known as epitopic suppression which occurs when subjects immunised with a recombinant bacterial vaccine fail to develop an appropriate immune response due to pre-existing immunity to the bacterial vector. Following completion of his PhD, Chris spent six years as a postdoctoral research scientist during which he developed and patented two key technologies. The first was a new live-attenuated vaccine against disease-causing Salmonella paratyphi A. The patent for the vaccine has since been licensed to an Indian biotechnology company. The second was a DNA vector platform for use in a live-attenuated bacteria that enables foreign gene expression in bacteria without antibiotic resistance markers.

Chris is also a strong contributor to the research and start-up sector, providing education and mentoring on the topics of identifying, protecting and leveraging multinational clients.

Chris comes to Pearce IP from the multinational firm K & L Gates where he has provided strategic advisory and prosecution services for Australian and multinational firms.

Chris Vindurampulle Awards 

World Intellectual Property Review (WIPR)

Diversity Champions in IP (2024)
WIPR Leader for Patents and Trade Marks (2023)

Managing IP Stars:

Rising Star (2021, 2022, 2023)

IAM Patent 1000:

Bronze ranking - Prosecution (2024)
Recommended for prosecution (2022, 2023)

Pearce IP Awards

Chambers and Partners 

Intellectual Property – Tier 5 (2024, 2023) 

Legal 500 Asia Pacific 

Ranked as a Market Leading Intellectual Property Firm (2024
Ranked as a Market Leading Intellectual Property Firm (2023

IAM Patent 1000 

Pearce IP ranked bronze for litigation and prosecution (2024, 2023, 2022, 2021

Australian Law Awards (Lawyers Weekly) 

Finalist - Boutique Diversity Firm of the Year (2022
Finalist – Intellectual Property Team of the Year (2022
Winner – Intellectual Property Team of the Year (2021

Managing IP Stars 

Pearce IP ranked Tier 3 – prosecution (2022
Pearce IP ranked firm (2021) 

Lawyers Weekly Women in Law Awards 

Boutique Diversity Firm of the Year – Finalist (2022

Women in Business Law Awards - APAC 

Shortlisted - Australian Firm of the Year (2022

Lexology Legal Influencer 

Healthcare and Life Sciences (Australasia) (Q4 2023, Q3 2023, Q2 2023,Q3 2022,  Q2 2022, Q1 2021, Q4 2020
Healthcare and Life Sciences (Cross-border) (Q4 2023, Q3 2023, Q2 2023, Q1 2023

Australasian Lawyer 5-Star Awards 

5-Star Intellectual Property Law Firm (2021

Doyles Intellectual Property 

Doyles Leading Intellectual Property (2021, 2020) 

Doyles Recommended Intellectual Property (2021)

Prosecution (Bronze) - IAM Patent 1000, 2024

“a frequent contributor to the research and start-up sector, providing education and mentoring on the topics of identifying, protecting and leveraging intangible assets”

"Winner - Intellectual Property Team of the Year 2021"

Australian Law Awards (Lawyers Weekly)

"Finalist - Intellectual Property Team of the Year 2022"

Australian Law Awards (Lawyers Weekly)

"Pearce IP bronze ranking for litigation and recommended for prosecution"

IAM Patent 1000 2021

"Pearce IP ranked bronze for litigation and prosecution"

IAM Patent 1000 2022

"5-Star Intellectual Property Law Firm"

Australasian Lawyer 5-Star Awards 2021

"Pearce IP Ranked Tier 3 - Prosecution"

MIP IP Stars 2022

"Lexology Legal Influencer"

Healthcare and Life Sciences (Australasia): Pearce IP (Q2 2022, Q1 2021, Q4 2020)

Healthcare and Life Sciences (Cross-border): Pearce IP (2021)

"Women in Business Law Awards - APAC"

Shortlisted: Australian Firm of the Year (2022)

The Legal 500, 2023, Intellectual Property, Australia

The Pearce IP team has an in depth understanding of the science and the pharmaceutical regulatory industry driving many of their client’s businesses.  They are passionate about achieving their client’s commercial objectives – and they are extremely hard-working and dedicated lawyers.

OUR VISION

By 2027, be the premier life sciences IP practice in
Australia and New Zealand.